

## Contents

**List of Contributors** XIII

**Foreword** XVII

**Timeline** XXI

**Introduction** XXIII

**Preface** XXIX

- 1 Global Epidemiology and Control of Tuberculosis** 1  
*Christopher Dye, Martien Borgdorff*
- 1.1 Introduction 1
- 1.2 Global and Regional Dynamics 3
- 1.3 Progress in the Implementation and Impact of TB Control 6
- 1.3.1 Vaccination 6
- 1.3.2 Preventive Therapy (Treatment of Latent TB Infection) 7
- 1.3.3 Treatment of Active TB 7
- 1.3.3.1 Case Detection 7
- 1.3.3.2 Treatment Success 8
- 1.3.3.3 Impact of DOTS on Incidence, Prevalence and Mortality 9
- 1.4 Achieving the Millennium Development Goals by 2015 11
- 1.5 Eliminating TB in the 21st Century 13
- 1.6 Conclusions 16
- References 17
- 2 Surveillance Studies and Interpretation** 23  
*Helen Ayles, Nulda Beyers, Donald A. Enarson, Peter Godfrey-Faussett*
- 2.1 Introduction 23
- 2.2 Surveillance of TB Infection 24
- 2.2.1 Rationale for Surveys of TB Infection 24
- 2.2.2 Standardization 25
- 2.2.3 Sample Selection, Sample Size and Design 26
- 2.2.3.1 Prevalence of Infection 26
- 2.2.3.2 Trend in Prevalence 27

2.2.3.3	Incidence of Infection	27
2.2.4	Difficulties in Interpretation	27
2.2.5	Conducting the Survey	28
2.2.6	Analysis and Calculations	28
2.2.7	Alternative Methods	29
2.3	Surveys of TB Disease	29
2.3.1	Rationale for Surveys of TB Disease (Prevalence Surveys)	29
2.3.2	Sample Selection	30
2.3.3	Case Detection	31
2.3.3.1	Sputum Culture	31
2.3.3.2	Sputum Smear	31
2.3.3.3	Chest X-ray Screening	31
2.3.3.4	Symptom Screening	32
2.3.3.5	Tuberculin Skin Testing	32
2.3.4	Conducting the Survey	32
2.3.5	Analysis	33
2.4	Surveillance for Drug Resistant TB	33
2.4.1	Rationale for Drug Resistance Surveillance	33
2.4.2	Sample Selection	34
2.4.3	Laboratory Approach	36
2.5	Conclusion	38
	References	39
<b>3</b>	<b>Molecular Epidemiology of <i>Mycobacterium tuberculosis</i></b>	<b>41</b>
	<i>G.D. Van der Spuy, R.M. Warren</i>	
3.1	Introduction	41
3.2	The Purpose of Molecular Epidemiology	42
3.3	Requirements for the Successful Application of Molecular Epidemiology	42
3.3.1	The Marker	42
3.3.2	The Analytical Tools	43
3.4	Genotyping Methods	43
3.4.1	Repetitive Sequences	43
3.4.1.1	Polymorphic GC-rich Repetitive Sequence Typing	44
3.4.1.2	Variable Number Tandem Repeats (VNTR)	44
3.4.1.3	MIRU-VNTR	44
3.4.1.4	Spoligotyping	46
3.4.2	Insertion Sequences	47
3.4.2.1	IS6110 Restriction Fragment Length Polymorphism (RFLP)	47
3.4.2.2	Mixed Linker	48
3.4.3	Single Nucleotide Polymorphisms (SNPs)	48
3.4.4	FAFLP	49
3.5	Epidemiological Interpretation	49
3.5.1	Evolution of Genetic Markers and Nearest Genetic Distance	51

3.6	Application of Molecular Epidemiology	51
3.6.1	<i>M. tuberculosis</i> Population Structure	51
3.6.2	Transmission vs Reactivation	52
3.6.3	Casual Contact	52
3.6.4	Where Transmission Occurs	52
3.6.5	Mapping of Outbreaks	52
3.6.6	Risk Factors for Transmission	53
3.6.7	Transmission from Smear Negative Cases	53
3.6.8	Recurrent Tuberculosis	53
3.6.9	Mixed Infection	54
3.6.10	Laboratory Error	54
3.6.11	Drug Resistance	55
3.6.12	Insights into the Global TB Epidemic at the Level of the Pathogen	55
3.6.13	Genotype–Phenotype	55
3.6.14	Vaccines and Clinical Trials	56
3.7	Summary	56
	References	57
<b>4</b>	<b>Clinical Diagnosis of <i>M. tuberculosis</i> Infection</b>	<b>63</b>
	<i>T. Mark Doherty</i>	
4.1	Introduction	63
4.2	Basic Diagnostic Algorithms	63
4.3	Sample Collection	65
4.4	Smear Microscopy	66
4.5	Culture	67
4.5.1	Solid Media	68
4.5.2	Liquid Media	68
4.6	Phage Tests	69
4.7	PCR	70
4.8	Radiology	71
4.9	Immunodiagnosis	72
4.10	The Tuberculin Skin Test	72
4.11	Interferon- $\gamma$ Release Assays	74
4.12	Future Developments	76
	References	78
<b>5</b>	<b>Clinical Features of Tuberculosis</b>	<b>89</b>
	<i>Philip C. Hopewell</i>	
5.1	Introduction	89
5.2	Systemic Features of TB	90
5.3	Pulmonary TB	91
5.3.1	Medical History and Physical Examination	92
5.3.2	Radiographic Evaluation	92
5.3.3	Obtaining Specimens for Microbiological Evaluation	96
5.4	Extrapulmonary TB	97

5.5	Lymph Node TB	98
5.6	Pleural TB	99
5.7	Bone and Joint TB	101
5.8	Central Nervous System TB	103
5.9	Abdominal TB	105
5.10	Genitourinary TB	106
5.11	Pericardial TB	107
5.12	Disseminated TB	109
	References	111
<b>6</b>	<b>Tuberculosis Control: Good Clinical Care and Good Public Health</b>	<b>115</b>
	<i>Dermot Maher</i>	
6.1	Introduction	115
6.2	The Need for Global TB Control	116
6.3	Identifying the Main Strategic Approaches to TB Control	116
6.3.1	The TB Disease Cycle	116
6.3.2	Main Strategic Approaches	117
6.3.2.1	BCG Immunization	117
6.3.2.2	Preventive Treatment	117
6.3.2.3	Physical Measures to Decrease Transmission	118
6.3.2.4	Case Detection and Successful Treatment	118
6.4	Basic Principles in TB Care	119
6.4.1	Establish Prompt and Accurate Diagnosis	119
6.4.1.1	Pulmonary TB	119
6.4.1.2	Extrapulmonary TB	120
6.4.2	Use Effective Standardized Drug Treatment	121
6.4.2.1	Effective Treatment Regimens	121
6.4.2.2	Comprehensive Approach to Promoting Adherence	121
6.4.2.3	Promoting Individual Civil Liberties and Public Health	122
6.4.2.4	Patients' Rights and Responsibilities	122
6.4.2.5	Assessment of Adherence	122
6.4.2.6	Access to Treatment	123
6.4.3	Monitor the Response to Treatment	123
6.4.4	Carry Out Essential Public Health Responsibilities	123
6.4.4.1	Contact Tracing	124
6.4.4.2	Reporting	124
6.5	The Evolution of the Strategic Approach to Global TB Control	124
6.5.1	The Development of the DOTS Strategy	124
6.5.2	The WHO Stop TB Strategy	125
	References	127
<b>7</b>	<b>Chemotherapy of Tuberculosis</b>	<b>131</b>
	<i>Neil W. Schluger</i>	
7.1	Introduction	131
7.1.1	Pre-Chemotherapy Era	131

7.1.2	The Chemotherapy Era	131
7.2	Current Therapy for TB	133
7.2.1	Drugs Used to Treat TB	133
7.2.2	General Principles for the Treatment of Pulmonary TB	134
7.2.3	Specific Regimens	135
7.2.4	Adherence	137
7.2.5	Dosing Schedules	137
7.2.6	Risk of Treatment Failure	138
7.2.7	Individual Drugs	139
7.2.7.1	Isoniazid	139
7.2.7.2	Rifampin	139
7.2.7.3	Pyrazinamide	140
7.2.7.4	Ethambutol	140
7.2.7.5	Sreptomycin	140
7.2.7.6	Other Agents	140
	References	141
<b>8</b>	<b>TB Drug Discovery from Target Identification to Proof of Concept Studies</b>	<b>143</b>
	<i>Thomas Dick, Véronique Dartois, Thomas H. Keller, Alex Matter</i>	
8.1	Introduction	143
8.2	The Evolution of Drug Discovery	144
8.3	Target Finding	146
8.4	Lead Finding	150
8.5	Lead Optimization	151
8.6	Proof of Concept Studies in Early Clinical Development	155
	References	159
<b>9</b>	<b>Latent Tuberculosis Infection</b>	<b>165</b>
	<i>C. Robert Horsburgh Jr</i>	
9.1	Background	165
9.2	Pathophysiology of Latent TB	165
9.3	Diagnosis of LTBI	167
9.4	Epidemiology of LTBI	169
9.4.1	Prevalence	169
9.4.2	Incidence	171
9.4.3	Risk of Reactivation TB among Individuals with LTBI	171
9.4.4	Risk Factors for Reactivation Disease	174
9.4.5	Treatment of LTBI	174
	References	176
<b>10</b>	<b>Clinical Management of Multidrug-Resistant Tuberculosis</b>	<b>181</b>
	<i>Sonya S. Shin, Félix Alcantara, Paul E. Farmer</i>	
10.1	Introduction	181

10.2	Epidemiology of MDR-TB	181
10.3	Diagnosis of Drug-Resistant TB	183
10.4	Treatment of Drug-Resistant TB	185
10.4.1	Directly Observed Therapy	185
10.4.2	Review of Antituberculous Agents	186
10.4.3	Individualized versus Standardized Approaches to MDR-TB Treatment	188
10.4.4	Initial Approach to MDR-TB Treatment	189
10.4.5	Principles of Foundation Design	190
10.4.5.1	Parenteral Agents	190
10.4.5.2	First-line Agents	190
10.4.5.3	Fluoroquinolones	191
10.4.5.4	Remaining Second-line Agents	191
10.4.6	Principles of Regimen Reinforcement	191
10.4.7	Design of the Definitive Regimen	192
10.4.8	MDR-TB in Pediatrics and Obstetrics	194
10.4.8.1	Treatment of Children with MDR-TB	194
10.4.8.2	MDR-TB and Pregnancy	195
10.4.9	MDR-TB and HIV	197
10.4.10	Corticosteroids	197
10.4.11	Surgery	197
10.4.12	Addressing Other Barriers to Treatment Success	198
10.4.13	Monitoring Treatment Response and Completion of Treatment	198
10.4.14	Management of Individuals Exposed to MDR-TB	199
10.5	Conclusion	199
	References	205
<b>11</b>	<b>Novel Treatment Strategies for TB Patients with HIV Co-infection</b>	<b>213</b>
	<i>Ann M. Ginsberg</i>	
11.1	Introduction	213
11.2	Goals for Improving TB Treatment of Patients Co-infected with HIV	215
11.3	Approaches to Developing Improved Treatments for TB Patients Co-infected with HIV	215
11.4	Drugs in Clinical Development for a TB Indication and their Interactions with the Cytochrome P450 Enzymes	218
11.4.1	Fluoroquinolones: Gatifloxacin and Moxifloxacin	219
11.4.2	Diarylquinoline -TMC207	220
11.4.3	Nitroimidazoles – OPC67683 and PA-824	220
11.4.4	Pyrrole – LL-3858	221
11.4.5	Ethylenediamine – SQ109	221
11.5	Future Directions for Improving Treatment of TB Patients Co-infected with HIV	222
	References	222

<b>12</b>	<b>Mathematical Modeling of Tuberculosis Transmission Dynamics</b>	<b>227</b>
	<i>Ted Cohen, Caroline Colijn, Megan Murray</i>	
12.1	Introduction	227
12.2	Models	228
12.2.1	Simple Compartmental Models	228
12.2.2	Individual-based and Network Models	230
12.3	Natural History of TB Infection and Population-level Dynamics	231
12.3.1	A Basic TB Model	232
12.4	Modeling Interventions for TB Control	233
12.4.1	DOTS Strategy and Extensions	233
12.5	Adding Complexity: Drug-resistant TB and TB/HIV	234
12.5.1	Drug-resistant TB	234
12.5.2	TB/HIV	236
12.6	Important Areas of Uncertainty	237
	References	240
<b>13</b>	<b>BCG Vaccination: Epidemiology and Immunology</b>	<b>245</b>
	<i>Hazel M. Dockrell, Patricia Gorak-Stolinska, Laura C. Rodrigues</i>	
13.1	Introduction and Brief History	245
13.1.1	Introduction	245
13.1.2	Brief History	246
13.2	Efficacy of BCG in Protecting against TB	247
13.2.1	Efficacy against Different Forms of Disease	247
13.2.2	Variations in BCG Efficacy against TB	248
13.2.3	Duration of Efficacy	248
13.2.4	Efficacy of a Second Dose of BCG	248
13.2.5	Protection against Other Diseases and Non-specific Effects caused by BCG	249
13.2.6	Scar Formation and Adverse Events	250
13.3	Recommendations and Current Practices in BCG Vaccination	250
13.3.1	Vaccination Schedules	250
13.3.2	Route of Vaccination	251
13.3.3	Contraindications and Safety of BCG Vaccination in HIV-infected Infants	252
13.4	Proposed Biological Mechanisms for BCG Protection	252
13.4.1	Importance of Cell-mediated Immunity	252
13.4.2	Insights into Mechanisms of BCG Protection from the Mouse Model	252
13.4.3	Role of CD8 T cells in BCG-induced Protection	253
13.5	BCG Strains	253
13.5.1	Origins of BCG Strains	253
13.5.2	Genetic and Phenotypic Differences among BCG Strains	254
13.5.3	Reactogenicity of BCG Strains	255

13.5.4	Strain Differences may Exist but there is no Evidence these Affect Protective Efficacy in Man	256
13.6	Biological Basis for Variation in BCG Protection Against Pulmonary Disease	257
13.6.1	The Role of Environmental Mycobacteria	257
13.6.2	Role of Helminth Infections	257
13.7	Correlates of Protection	258
13.7.1	Cell-mediated Immunity is Clearly Necessary for Protection	258
13.7.2	Delayed-Type Hypersensitivity (DTH) does not Provide a Useful Correlate of Protection	259
13.7.3	<i>In vitro</i> T-Cell Immune Responses in Vaccinated Adults	259
13.7.4	Immune Responses Induced by BCG in Vaccinated Infants	262
13.7.5	Beyond IFN $\gamma$ . The Search for Correlates of Protection	262
13.7.6	Assays of Mycobacterial Growth Inhibition	263
13.8	Many of the New TB Vaccines under Development Aim to Improve the Immunity Given by BCG	263
	References	264

<b>Index</b>	277
--------------	-----